Transforming the lives of patients with pulmonary arterial hypertension.
Gossamer Bio, founded in 2015 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company listed on Nasdaq (GOSS). The company is focused on the development and commercialization of seralutinib, an inhaled kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). Gossamer raised $317 million in its 2019 IPO and has a global collaboration with the Chiesi Group for seralutinib development, providing milestone payments and cost reimbursements.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2023
Jul 2022
Jul 2018
Jan 2018
Jan 2018
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
